I am a
Home I AM A Search Login

Papers of the Week

2022 Mar 11

Ital J Dermatol Venerol

Biosimilar versus originator etanercept: a real-life clinical study.


Giordano D, Capalbo A, Gagliostro N, Fedele G, Balampanos CG, Persechino F, Bushati V, Ulisse S, Persechino S, Pellacani G
Ital J Dermatol Venerol. 2022 Mar 11.
PMID: 35274881.


Over the last few years, novel therapeutic approaches based on the use of monoclonal antibodies against cytokines, or their cognate receptors, involved in psoriasis progression have shown remarkable results, being capable to reduce disease progression and increase patient's quality of life. Among these is etanercept (Enbrel®, Pfizer, Sandwich, UK) and its biosimilar compound SB4 (Benepali®, Samsung Bioepis, Delft, The Netherlands), both approved for the treatment of moderate to severe psoriasis. Aim of the present study was to evaluate in a less controlled environment, such as real-life, the actual bioequivalence between the etanercept (ETN) and the SB4 in term of safety, efficacy and patient's quality of life.